BIA
PTGX icon

Bell Investment Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Bell Investment Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5K Buy
86
+5
+6% +$522 ﹤0.01% 689
2026
Q1 		$8.54K Hold
81
– – ﹤0.01% 744
2025
Q4 		$7.08K Hold
81
– – ﹤0.01% 832
2025
Q3 		$5.38K Hold
81
– – ﹤0.01% 900
2025
Q2 		$4.48K Buy
81
+50
+161% +$2.4K ﹤0.01% 1032
2025
Q1 		$1.5K Buy
31
+14
+82% +$587 ﹤0.01% 1416
2024
Q4 		$657 Hold
17
– – ﹤0.01% 1696
2024
Q3 		$765 Hold
17
– – ﹤0.01% 1672
2024
Q2 		$590 Hold
17
– – ﹤0.01% 1750
2024
Q1 		$492 Buy
+17
New +$463 ﹤0.01% 1829

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bell Investment Advisors's PTGX Position: Q2 2026 in Review

Bell Investment Advisors increased its Protagonist Therapeutics (PTGX) stake by 6.2% in Q2 2026, buying an estimated $522 and bringing the position to 86 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #689.

Bell Investment Advisors first reported a position in PTGX in Q1 2024 and has held it in 10 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Bell Investment Advisors held 86 shares of Protagonist Therapeutics worth $10.5K as of Q2 2026.
  • Bell Investment Advisors bought 5 Protagonist Therapeutics shares in Q2 2026, an estimated $522.
  • Protagonist Therapeutics made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #689 holding.
  • Bell Investment Advisors first reported a position in Protagonist Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.